Decision Diagnostics Corp (DECN)

[nonsequetor]

From that same article:

Strong Bio is not enthusiastic about investing in penny stocks, noting a less than stellar track record of personal performance and a history of being very risky. But it is likely that Johnson & Johnson, like Pfizer, might gobble up this "diagnosimilar." DECN may not have yet had a fair chance to compete in the marketplace to determine value, so the market cap of $2 million may be artificially low. DECN is sometimes criticized by skeptics for not focusing on developing its product line (and filing timely financials) instead of focusing on legal issues. For that reason in addition to its legal impediments, it is now listed on the Pink Sheets exchange. But one might put this on the watch list just because it is interesting to follow. Moreover, the same changing legal landscape enabled predicate investment success in the case of Vringo with its patent troll battle.

https://seekingalpha.com/article/4060752-4-companies-stand-benefit-lower-healthcare-prices